Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
Status:
Recruiting
Trial end date:
2023-02-21
Target enrollment:
Participant gender:
Summary
The primary objective of this phase 1b study is to evaluate the safety and tolerability of
blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum
tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with
continuous intravenous infusion (cIV) blinatumomab.